SAR425899
Total Payments
$1.2M
Transactions
688
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $715,154 | 6 | 0 |
| 2018 | $160,091 | 88 | 3 |
| 2017 | $368,973 | 594 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 668 | 97.3% |
| Consulting Fee | $25,932 | 3 | 2.1% |
| Travel and Lodging | $6,074 | 11 | 0.5% |
| Food and Beverage | $1,145 | 6 | 0.1% |
Payments by Type
Research
$1.2M
668 transactions
General
$33,151
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Repeated Subcutaneous Doses of SAR425899 on Energy Expenditure and Safety in Overweight to Obese Male and Female Subjects | SANOFI US SERVICES INC. | $705,634 | 0 |
| A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus | SANOFI US SERVICES INC. | $337,283 | 0 |
| A randomized, comparative, open label study to assess the safety and tolerability of 3-arm, parallel, repeated subcutaneous dose regimens of SAR425899 in overweight to obese subjects and T2DM patients | SANOFI US SERVICES INC. | $93,941 | 0 |
| A Randomized, Comparative, Open Label Study to Assess the Safety and Tolerability of 3-arm, Parallel, Repeated Subcutaneous Dose Regimens of SAR425899 in Overweight to Obese Subjects and T2DM Patients | SANOFI US SERVICES INC. | $46,655 | 0 |
| Gastro Emptying Study - INT1 - Drug interaction | SANOFI US SERVICES INC. | $27,554 | 0 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $1.2M
- SANOFI-AVENTIS U.S. LLC $33,151
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 3
- Transactions 688
About SAR425899
SAR425899 is a drug associated with $1.2M in payments to 3 healthcare providers, recorded across 688 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $715,154 was paid across 6 transactions to 0 doctors.
The most common payment nature for SAR425899 is "Unspecified" ($1.2M, 97.3% of total).
SAR425899 is associated with 5 research studies, including "A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Repeated Subcutaneous Doses of SAR425899 on Energy Expenditure and Safety in Overweight to Obese Male and Female Subjects" ($705,634).